Summary The purine analogue 2-chlorodeoxyadenosine (CdA) is unique compared with traditional antimetabolite drugs, as it has shown equal activity in dividing and resting lymphocytes. Poly(ADP-ribose)polymerase (PARP) activation and consecutive NAD+ consumption have been associated with the induction of apoptosis in resting cells. The potential of CdA to induce the p53-dependent DNA damage response was assessed in resting and phytohaemagglutinine (PHA)-activated peripheral blood mononuclear cells (PBMCs) and compared with cisplatin (DDP), a cell cycle-dependent and DNA-damaging agent that is mainly used in the treatment of solid tumours. Both drugs induced transactivation of the p53 target genes wafl and mdm2, NAD+ consumption and apoptotic death. The expression pattern of p53 and waf1 suggests a partly p53-independent induction of waf1. The expression of c-myc and PARP, which both have a dual role in proliferation and apoptosis, was selectively induced by CdA. Cell cycle stimulation increased the cytotoxic activity of both drugs. These data show that DDP is also a potent inducer of apoptosis in resting and proliferating peripheral blood mononuclear cells. Activation of the p53-dependent DNA damage response seems to be an important component of the toxic effect of CdA.
Apoptosis is a genetically controlled physiological mechanism, by which eukaryotic organisms remove their own unwanted cells. It ensures homeostasis, as for each newly formed cell another cell has to die to keep a perfect balance of cell numbers in the adult organism. This suggests that the regulation of apoptosis and the regulation of proliferation are highly intertwined. The development of cancer can be viewed as a derangement of this balance. However, malignant transformation by various oncogenes renders cancer cells more susceptible to apoptosis induction in an attempt to counterbalance proliferation (Fisher, 1994) . This altered set point of apoptosis induction in cancer cells is one reason for the beneficial therapeutic ratio of chemotherapy. Despite a large variety of specific drug-target interactions, most anti-cancer agents kill cancer cells by inducing apoptosis (Hickman, 1992; Bomer et al, 1995) . Recent evidence provides further support for a link between proliferation and apoptosis, as the same genes are involved in the regulation of the cell cycle and of chemotherapy-induced apoptosis. Rapidly growing tumours seem to be more susceptible to chemotherapy (Bomer, 1996; St Croix, 1996; Stone et al, 1996) .
The induction of DNA damage is a central event for the action of many anti-cancer agents. However, whether DNA damage leads to apoptosis is critically dependent on the function of the p53 tumour-suppressor gene in the affected cell (Lowe et al, 1993; Fisher, 1994) . DNA damage increases the levels of p53, which in tum induces either growth arrest primarily at the G, phase of the cell cycle or apoptosis, depending on the cellular context (Oren, 1992; Vogelstein and Kinzler, 1992; Lane, 1993) . The p53 protein acts as a transcription factor and many of its biological effects are executed by transactivation of target genes, such as bax, waf] or mdm2 (El-Deiry et al, 1993; Chen et al, 1994; Miyashita and Reed, 1995) . However, p53-disabling mutations belong to the most prevalent genetic aberrations in human cancer, and this fact might contribute to the pleiotropic drug resistance of many tumours.
As most malignant tumours have both a low proliferative capacity and a dysfunctional p53 tumour-suppressor gene, agents with a proliferation and p53-independent mechanism of action are very attractive for the treatment of cancer. The drug 2-chlorodeoxyadenosine (CdA), a purine analogue with distinct activity in lymphoproliferative disorders of low-grade malignancy, has been described to be equally active against dividing and resting lymphocytes (Saven and Piro, 1994) . CdA produces DNA strand breaks in resting lymphocytes, probably by interfering with the repair of spontaneously occurring DNA strand breaks. This activates the DNA repair enzyme poly(ADP-ribose)polymerase (PARP), which is dependent on NAD+ for the synthesis of poly(ADP-ribose). It has been speculated that CdA stimulates disproportionate NAD+ consumption by this mechanism, which leads to apoptotic death (Seto et al, 1985 (Seto et al, , 1986 . According to these data, apoptosis by CdA is induced by NAD+ consumption and should not be critically dependent on p53 function.
Because of this presumably unique activity of CdA compared with traditional antimetabolite drugs (Saven and Piro, 1994) , we were interested in the mechanism, specificity and proliferation dependence of its effect. CdA was compared with cisplatin (DDP), an alkylating metal complex compound with well-described intracellular targets (Reed et al, 1996) . In contrast to CdA, DDP induces DNA strand breaks and apoptosis mainly in proliferating cells (Evans and Dive, 1993; Demarcq et al, 1994) . Human peripheral blood mononuclear cells (PBMCs) were chosen as the model system for our studies because of the lymphotropic activity of CdA. 
Cytotoxicity assays
Cytotoxicity was assessed using the Alamar Blue (Alamar, Sacramento, CA, USA) oxidation-reduction indicator, which changes from blue (oxidized) to red (reduced) in response to metabolic activity (Page et al, 1993) . The dye was added at a final concentration of 10% at the indicated time points, incubated for 24 h and then measured using an excitation wavelength of 560 nm and an emission wavelength of 590 nm with a CytoFluor II platereader (PerSeptive Biosystems, Framingham, MA, USA).
Analysis of DNA integrity DNA integrity was assessed as described (Borner et al, 1994 
Western blot analysis
Cells were collected and lysed in 80 mm Tris pH 6.8, 2% sodium dodecyl sulphate (SDS), 10% glycerol, 2% 2-0-mercaptoethanol and 0.02% bromophenol blue at 100°C for 3 min. Proteins were size fractionated on a 12% SDS-polyacrylamide gel and transferred to a Hybond nitrocellulose filter using a semi-dry electroblotting apparatus. Membranes were probed using a mouse monoclonal antibody against p53 (Ab-6, Oncogene Science) and visualized using a secondary goat anti-mouse antibody conjugated with horseradish peroxidase. Chemoiluminescence was performed with enhanced chemiluminescence (ECL) (Amersham Life Science).
Flow cytometry
Attached cells were brought into suspension using 5 mM EDTA, pelleted together with detached cells and washed in cold phosphate-buffered saline (PBS). The fresh samples were permeabilized with Triton X-100 at low pH in the presence of serum proteins (Darzynkiewicz et al, 1992) . The metachromatic dye acridine orange was used to identify simultaneously GO-and apoptotic cells by measuring cellular DNA and RNA content. Intercalated into double-strand DNA, acridine orange displays green fluorescence, dye-RNA interaction displays red fluorescence. As an altemative method to stain apoptotic cells, DNA strand breaks were labelled using the terminal deoxytransferase-mediated deoxyuridine nick end-labelling assay (TUNEL) (Gavrieli et al, 1992; Gorczyca et al, 1993) . After washing and fixation, cells were processed using the ApopTag in situ apoptosis detection kit according to the manufacturer's instructions (Appligene/Oncor). Flow cytometry was performed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA), and cell populations were quantitated using Cell Quest software. Apoptosis was morphologically confirmed by fluorescence microscopy. Figure 2 Agarose gel electrophoresis to detect DNA laddering. DNA from PBMCs exposed to 1 9g ml-' CdA (C) or to 10 9g ml-' DDP (D) was harvested at the indicated times after start of treatment NAD measurement NAD+ pools were measured using an enzymatic cycling assay (Bernofsky and Swan, 1973) . Each reaction tube contained 0.2 ml of either cell extract or NAD+ standard, 0.1 ml of alcohol dehydrogenase (160 U ml-') and 1 ml of reaction mixture consisting of 600 mm ethanol, 0.5 mm MTT, 2 mm phenazine ethosulphate, 5 mm EDTA, 1 mg of bovine serum albumin and 120 mM N-bis(2 hydroxyethyl)glycine, pH 7.8. The assay was initiated at 37°C in the dark and was terminated after 20 min by adding 0.5 ml of 12 mm iodoacetate. The optical density of reduced MTT was measured at 570 nm. All chemicals were purchased from Sigma Chemicals, Buchs, Switzerland.
RESULTS

Cytotoxic activity in unstimulated and stimulated PBMCs
PBMCs from individual healthy human blood donors were treated with CdA or DDP over a period of 72 h to assess the relative toxicity of these agents. To evaluate the impact of proliferative activity, parallel samples were stimulated with 10 gg ml-1 PHA while being exposed to the respective chemotherapeutic drug. After a 24-h treatment with PHA alone, 53% of the cells were in cell cycle compartments other than Go as quantified by flow cytometry.
The cytotoxic activity of CdA and DDP was assessed in several ways. First, Alamar Blue was used, a metabolic assay that has been validated against other colorimetric viability stains (Page et al, 1993) . After reduction in living cells, the Alamar Blue dye yields a very strong fluorescent substrate. PHA led to an increased toxicity of both chemotherapeutic drugs, but the difference was not significant. DNA integrity of treated and untreated PBMCs was analysed to assess whether the drugs induced apoptosis. DNA from parallel samples was extracted and separated on agarose gels. Figure 2 shows that treated cells displayed the intemucleosomal DNA fragmentation pattern characteristic of apoptosis with increasing intensity over time. However, CdA caused a more intensive DNA laddering than DDP despite equal cytotoxicity in the Alamar Blue assay. A possible explanation for this finding is that DDP led to an increase of membrane permeability, resulting in the loss of small DNA fragments as described for human prostate cancer cells (Bomer et al, 1995) . The TUNEL assay (Gavrieli et al, 1992; Gorczyca et al, 1993) was used as an additional method for the detection of apoptotic cells (Figure 3 ). Labelled cells were quantified by FACS analysis (Table 1) Both p53 and PARP are critically involved in the cellular response to DNA damage and the induction of apoptosis (Lane, 1993; Ashkenas and Werb, 1996) . Another DNA damage inducible gene is c-myc (Fornace et al, 1993) , which also has a central role in some forms of apoptosis (Bissonette et al, 1992; Evan et al, 1992; Shi et al, 1992) . Unstimulated and PHA-activated PBMC from individual donors were treated with CdA or DDP. DDP led only to a faint p53 induction at 18 h and showed no effect on c-myc or PARP mRNA levels ( Figure 4 A and B) . The function of p53 is known to be mainly regulated at the post-transcriptional level (Mosner et al, 1995) . We assessed p53 protein induction by Western blot. Figure 5 shows that both CdA and DDP led to a gradually increasing p53 protein induction over 48 h. Next, the induction of the p53 target genes wafi and mdm2 was examined as a measure of the biological activity of p53. CdA and DDP induced wafl and mdm2 in a parallel fashion ( Figure 4B ), which correlates well with the cytotoxic activity of the agents and their induction of p53 protein. Figure 1 . NAD+ was measured using an enzymatic cycling assay (Bernofsky, 1973) at 72 h. A typical example of three independent experiments is shown.
NAD+ consumption PARP activation and NAD+ consumption have been described as being important causes of apoptosis induction by CdA in resting cells (Seto et al, 1985 (Seto et al, , 1986 . Here, we considered the questions of whether this mechanism of action is specific for CdA and of how proliferation affects NAD+ consumption. CdA led to a more pronounced drop of cellular NAD+ levels in quiescent PBMCs than DDP. Stimulation by PHA led to a marked increase in cellular NAD+ production (Table 2) . However, this rise of consumable NAD+ had no protective effect on PBMCs. There was no direct correlation between NAD+ level and cytotoxic activity of the drugs. CdA and DDP treatment of growth-stimulated cells led to an even more complete NAD+ consumption compared with resting cells. At the RNA level, only CdA induced PARP expression ( Figure 4A ).
DISCUSSION
The precise biochemical changes by which CdA induces apoptosis are speculative (Bryson and Sorkin, 1993; Saven and Piro, 1994) . In dividing cells, potential targets are DNA synthesis and the ribonucleotide reductase (Griffig et al, 1989) . It has been proposed that the resulting deoxyribonucleoside triphosphate pool imbalance provides the signal for an endonuclease, which leads to internucleosomal DNA degradation and apoptosis (Hirota et al, 1989) . In non-dividing cells, CdA has been shown to induce DNA strand breaks, inhibition of RNA synthesis, a profound drop of NAD+, ATP depletion and apoptotic cell death. As shown by Seto et al (1985) , adding nicotinamide, a precursor of NAD+, prevented NAD+ depletion and partly protected PBMCs from the toxic effect of CdA, suggesting a causal role of NAD+ depletion for apoptosis. Our studies demonstrate that CdA and DDP are both strong inducers of apoptosis in resting and proliferating PBMCs, despite their presumably different biochemical mechanism of action. DDP damages DNA by inducing crosslinks and intrastrand adduct formation (Reed et al, 1996) . Compared with other systems (Evans and Dive, 1993; Demarcq et al, 1994) , cell cycle activity does not seem to be a requirement for the cytotoxic action of DDP in PBMCs. Also, we show here that both CdA and DDP led to NAD+ consumption. However, this result does not suggest a causal role of NAD+ consumption for apoptosis in this system, as the NAD+ content was higher in growth-stimulated apoptotic cells than in unstimulated controls (Table 2 ). This contrasts with the findings of Seto et al (1985) , which showed that the prevention of NAD+ depletion by nicotinamide rendered resting PBMCs highly resistant to CdA toxicity. However, others have found massive depletion of NAD+ to be a late event in apoptosis, which is rather the result of than the cause of cell death (Sorenson et al, 1990; Yoon et al, 1996) . Only CdA led to a significant PARP mRNA induction, despite the fact that NAD+ consumption was associated with both CdA and DDP activity. This is in accordance with other data showing PARP activity to be regulated dominantly at the posttranscriptional level (Bhatia et al, 1990a) . As CdA led to a slightly stronger p53 response and apoptosis induction than DDP, it can be speculated that other triggering events in addition to DNA damage were present. CdA has been shown to lead to a depletion of ribonucleotides (Griffig et al, 1989; Hirota et al, 1989 ) and this has recently been described as being a DNA damage-independent inductor of p53 (Linke et al, 1996) .
Many of the functions of p53 require transactivation of target genes, such as wafi or mdm2. Mdm2 serves as an autoregulatory feedback loop for p53 (Momand et al, 1992; Chen et al, 1994) .
Waf1 is a cyclin-dependent kinase inhibitor and orchestrates GI arrest to allow damage repair before the cell starts DNA replication (El-Deiry et al, 1993; Harper et al, 1993) . Determination of the mechanism by which p53 induces apoptosis has been more elusive, and the mechanism seems to be independent of wafl (Deng et al, 1995) . We were interested in the effect of CdA on p53 as, according to the literature (Seto et al, 1985) , energy depletion rather than DNA damaging seems to be the prevailing mechanism of CdA toxicity in non-dividing human lymphocytes. The pattem of wafl induction by CdA and DDP suggests similar kinetics and quantity of the DNA-damaging activity of the two drugs. Despite repeated experiments, inconsistencies between p53 mRNA, p53 protein and wafl induction remained. However, there have been observations that higher doses of DNA-damaging agents can circumvent this absolute requirement for p53, suggesting altemative p53-independent pathways for wafl induction (Michieli et al, 1994) .
PARP, c-myc and p53 have all been shown to play a dual role in apoptosis and proliferation (Mercer and Baserga, 1985; Reed et al, 1986; Bhatia et al, 1990b; Evan et al, 1992) , suggesting common molecular pathways for these seemingly opposite cell fates. In accordance with this dual role, these genes were similarly induced by CdA treatment and mitogen stimulation in our experiments. Whether c-myc expression is associated with apoptosis or proliferation depends upon the signaling context in a given cell. If activated in cells that are not naturally destined to undergo growth stimulation, this conflicting signal can induce apoptosis (Evan et al, 1992) . Colombel et al (1992) have shown that castrationinduced apoptosis in quiescent epithelial prostate cells is associated with the exit from the Go state into a defective cell cycle (Colombel et al, 1992) . The fact that the cytotoxic action of DDP did not require early p53, c-myc and PARP induction suggests that this pathway is not an absolute requirement for apoptosis to proceed in PBMCs.
Our data support the notion that CdA is a potent inducer of apoptosis in non-dividing lymphoid cells, which gives a rationale for the exceptional clinical activity of this drug against indolent lymphoid malignancies. DDP is mostly used for the treatment of solid tumours, in which it is the comerstone of a variety of curative treatment regimens. However, DDP has also been successfully integrated into treatment regimens against aggressive lymphoid British Joumal of Cancer (1997) 76 (11), [1448] [1449] [1450] [1451] [1452] [1453] [1454] malignancies. The fact that both anti-cancer drugs were strong inducers of apoptosis in resting and stimulated PBMCs might reflect the low threshold for apoptosis induction of human lymphoid cells (Fisher, 1994) . Although previous research into the activity of CdA and DDP has focused on different intracellular targets, we have shown that both drugs activated p53 target genes and led to significant NAD+ consumption. Also in view of its limited non-haematological toxicity (Saven and Piro, 1994) , CdA could be a very attractive agent in the treatment of cancer.
However, the activity of CdA in solid tumours is limited by the low ratio of deoxycytidine kinase to 5'-deoxynucleotidase in these tissues, preventing intracellular activation of CdA (Kawasaki et al, 1993) . Manoeuvres to aid or circumvent this activation step should help to broaden the spectrum of this interesting drug to nonlymphoid malignancies.
